Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1-BCMA Bispecific CAR T in RRMM
NCT04662099Phase 1Unknown
- Start
- Mar 2020
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CS1-BCMA bispecific CAR T cells in multiple myeloma (MM). Primary endpoint: Incidence of Treatment-related Adverse Events at 2 years. Status: unknown.
02
Drugs
CS1-BCMA bispecific CAR T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04662099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662099.